![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Efficacy of Vaniprevir (MK-7009) in Combination with Peg-interferon a-2a (Peg-IFN)/Ribavirin (RBV) in Genotype 1 Treatment-Experienced HCV-Infected Japanese Patients
|
|
|
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
Norio Hayashi1, Keisuke Nakamura2, Duncan Hamish Wright3, Luzelena Caro3, Richard J Barnard3, Niloufar Mobashery3, Yoshiyuki Tanaka2
1Kansai Rosai Hospital, Hyogo, Japan, 2MSD KK, Tokyo, Japan, 3Merck Sharp & Dohme Corp, Whitehouse Station, NY, USA
AASLD: A Phase 2b Study of MK-7009 (vaniprevir) in Patients with Genotype 1 HCV Infection Who HaveFailed Previous Pegylated Interferon and Ribavirin Treatment - (11/15/11)
Safety, Tolerability and Antiviral Activity of MK-7009, a Novel ...
MONOTHERAPY 8 Days
Safety, Tolerability and Antiviral Activity of MK-7009, a Novel Inhibitor of the Hepatitis C Virus NS3/4A Protease, in Patients with Chronic HCV Genotype 1 Infection
![AASLD1.gif](../images/111611/111611-3/AASLD1.gif)
![AASLD2.gif](../images/111611/111611-3/AASLD2.gif)
![AASLD3.gif](../images/111611/111611-3/AASLD3.gif)
![AASLD4.gif](../images/111611/111611-3/AASLD4.gif)
![AASLD5.gif](../images/111611/111611-3/AASLD5.gif)
![AASLD6.gif](../images/111611/111611-3/AASLD6.gif)
![AASLD7.gif](../images/111611/111611-3/AASLD7.gif)
![AASLD8.gif](../images/111611/111611-3/AASLD8.gif)
![AASLD9.gif](../images/111611/111611-3/AASLD9.gif)
![AASLD10.gif](../images/111611/111611-3/AASLD10.gif)
![AASLD11.gif](../images/111611/111611-3/AASLD11.gif)
![AASLD12.gif](../images/111611/111611-3/AASLD12.gif)
![AASLD13.gif](../images/111611/111611-3/AASLD13.gif)
![AASLD14.gif](../images/111611/111611-3/AASLD14.gif)
![AASLD15.gif](../images/111611/111611-3/AASLD15.gif)
![AASLD16.gif](../images/111611/111611-3/AASLD16.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|